Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards

Aclaris Therapeutics, Inc.

Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.
Neal Walker appointed Interim CEO; receives $500,000 base salary, bonus eligible at 60% of base.
Granted stock option for 497,000 shares at $1.20 per share, vesting monthly over 15 months.
Also granted RSU for 142,000 shares with same 15-month monthly vesting and change-in-control acceleration.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Neal Walker

Interim Chief Executive Officer and President

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-01-17
Filed: February 5, 2024, 6:59 PM ET

in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.

Departed

Douglas Manion

Chief Executive Officer and President

ACRS · Aclaris Therapeutics, Inc.

Effective: 2024-01-16
Successor: Neal Walker
Filed: February 5, 2024, 6:59 PM ET

On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Neal Walker was appointed as Interim Chief Executive Officer and President at Aclaris Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Douglas Manion resigned as Chief Executive Officer and President at Aclaris Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer and President

Exact text from the filing

On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-000770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.